News

By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J., November 6, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA® (pembrolizumab) – the […]

KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH, November 16, 2014 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 […]

Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company’s Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company’s oncology and […]

Study Failed to Meet Secondary Endpoint of Overall Survival THOUSAND OAKS, Calif., Nov. 4, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not […]

October 27, 2014 – WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma […]

The new care pathway for advanced pelvic cancer encourages knowledge transfer and multidisciplinary care Stockholm, Sweden – 17 October 2014 – GE Healthcare and Karolinska University Hospital in Stockholm, Sweden, have established a partnership to improve the efficiency of the care pathway for pelvic cancer patients and reduce unwarranted clinical variation. GE Healthcare will be […]

Low Level of Awareness Revealed About Breast Density and Lower Accuracy of Mammogram Screening for Dense Breasts NEW YORK, NY, October 8, 2014–A new survey entitled “Diagnosis Anxiety: The Working Mother Breast Screening Report” sheds important new information on the level of awareness women have about breast cancer today and what they are doing to […]

Important risk factor for breast cancer still not widely-known: only one out of five people globally has seen, heard or read about dense breast tissue in the last six months Countries with low awareness that dense breast tissue is an increased risk factor for developing breast cancer include UK, USA, Japan and South Korea – […]

Allegheny, PA, October 1, 2014 — Allegheny Health Network is the first center in the nation to install SenoClaire*, GE Healthcare’s (NYSE: GE) new breast tomosynthesis solution designed with a three-dimensional imaging technology. SenoClaire, which was approved by the FDA earlier this month, uses a low-dose short X-ray sweep around the positioned breast with nine […]

Aliso Viejo, CA – September 30, 2014 – GE Healthcare today announced an agreement between its affiliate, Clarient Diagnostic Services, Inc. (Clarient) and GlaxoSmithKline (GSK). The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types. The collaboration […]